Prevest Denpro Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Healthcare Equipment & Supplies | Market Cap: ₹458 Cr
The US business is expected to grow significantly over the next 2-3 years, driven by private labeling and online sales, with aggressive participation in US exhibitions. The company demonstrated steady growth with a 13.9% increase in revenue and 12.9% growth in profit after tax for FY 2025-26.
From Prevest Denpro Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹403
Market Cap
₹458 Cr
P/E Ratio
21.4
Revenue Rank
Margin Rank
How does Prevest Denpro Ltd rank in Healthcare Equipment & Supplies?
Compare Prevest Denpro Ltd against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
Prevest Denpro Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹19 Cr, net profit ₹6 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →The US business is expected to grow significantly over the next 2-3 years, driven by private labeling and online sales, with aggressive participation in US exhibitions.
- →Digital dentistry revenue, especially 3D printing resins, grew 40% this year; 3D printer sales rose by 162%, indicating strong growth potential, with plans for an indigenous 3D printer by 2028.
- →Export markets are expected to expand with new international market entries and subsidiaries in the USA and UAE contributing to growth.
- →Domestic sales are projected to increase through expanded distribution in Tier 2 and Tier 3 cities and enhancing sales team strength.
- →New product launches in the Oradox oral health segment and disinfectants business anticipate boosting revenues.
- →Overall company sales grew 13.9% YoY; continued strategic focus suggests steady growth, despite geopolitical challenges.
- →Innovation and digital dentistry segments are prioritized for high growth in coming years.
📈 Profitability & Margins
Rank 3- →The company demonstrated steady growth with a 13.9% increase in revenue and 12.9% growth in profit after tax for FY 2025-26.
- →EBITDA margin improved to 40.87% in Q4, highlighting operational efficiency.
- →Strong focus on innovation, especially in digital dentistry and 3D printing, expecting these to drive significant growth.
- →Plans to launch new products and expand disinfectant and oral health portfolios.
- →Expansion in the US and UAE subsidiaries anticipated to boost international sales.
- →Positive outlook on domestic business growth driven by deeper market penetration in Tier 2 and Tier 3 cities.
- →Projected rise in OEM partnerships to increase sales.
- →Targeting an indigenous 3D printer launch by 2028, expected to strengthen competitive positioning.
- →Confidence in sustainable long-term value creation through disciplined capital allocation and operational excellence.
🏗️ Capital Expenditure Plans
Yes- →Prevest DenPro is actively investing in the development of a fully indigenous 3D printer, targeting commercialization by 2028, enhancing their digital dentistry portfolio.
- →The company is expanding its disinfectant business vertical, with plans to invest in broadening its product portfolio in a disciplined, phased manner over the coming years.
- →Continuous investment is being made in advanced digital solutions and research and development to strengthen leadership in digital dentistry.
- →The company is working on import substitution for key raw materials, reducing dependency on foreign suppliers, which is part of their capital and R&D efforts.
- →Subsidiaries in the UAE and the U.S. are strategic investments to enhance market presence and direct customer engagement internationally.
- →Overall, investments focus on capacity utilization increase, production line expansions especially in digital dentistry, resin, disinfectants, and oral health segments.
💰 Fundraising & Capital Structure
No information📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Prevest Denpro Ltd Q1 FY27 results?
The US business is expected to grow significantly over the next 2-3 years, driven by private labeling and online sales, with aggressive participation in US exhibitions. The company demonstrated steady growth with a 13.9% increase in revenue and 12.9% growth in profit after tax for FY 2025-26.
What is Prevest Denpro Ltd share price analysis?
Prevest Denpro Ltd currently shows a below-average growth signal. The stock trades at a P/E of 21.4 with a market cap of ₹458 Cr. Investors should review the full earnings analysis for detailed insights.
Is Prevest Denpro Ltd planning capital expenditure?
Prevest DenPro is actively investing in the development of a fully indigenous 3D printer, targeting commercialization by 2028, enhancing their digital dentistry portfolio. - The company is expanding its disinfectant business vertical, with plans to invest in broadening its product portfolio in a disciplined, phased manner over the coming years. - Continuous investment is being made in advanced digital solutions and research and development to strengthen leadership in digital dentistry. - The company is working on import substitution for key raw materials, reducing dependency on foreign suppliers, which is part of their capital and R&D efforts. - Subsidiaries in the UAE and the U.S.
Keep Prevest Denpro Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.